Saltar al contenido
Merck

YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression.

Oncogene (2015-03-24)
C He, X Lv, G Hua, S M Lele, S Remmenga, J Dong, J S Davis, C Wang
RESUMEN

Mechanisms underlying ovarian cancer initiation and progression are unclear. Herein, we report that the Yes-associated protein (YAP), a major effector of the Hippo tumor suppressor pathway, interacts with ERBB signaling pathways to regulate the initiation and progression of ovarian cancer. Immunohistochemistry studies indicate that YAP expression is associated with poor clinical outcomes in patients. Overexpression or constitutive activation of YAP leads to transformation and tumorigenesis in human ovarian surface epithelial cells, and promotes growth of cancer cells in vivo and in vitro. YAP induces the expression of epidermal growth factor (EGF) receptors (EGFR, ERBB3) and production of EGF-like ligands (HBEGF, NRG1 and NRG2). HBEGF or NRG1, in turn, activates YAP and stimulates cancer cell growth. Knockdown of ERBB3 or HBEGF eliminates YAP effects on cell growth and transformation, whereas knockdown of YAP abrogates NRG1- and HBEGF-stimulated cell proliferation. Collectively, our study demonstrates the existence of HBEGF & NRGs/ERBBs/YAP/HBEGF & NRGs autocrine loop that controls ovarian cell tumorigenesis and cancer progression.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
MISSION® esiRNA, targeting human YAP1
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Yap1
Sigma-Aldrich
MISSION® esiRNA, targeting human ERBB3
Sigma-Aldrich
MISSION® esiRNA, targeting human YY1AP1
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Erbb3